In The News,

Evaluation of Indication-Based Pricing for Oncology Biologic

Evaluated potential strategies to implement Indication Based Pricing (IBP) and understand the impact to ASP and other reimbursement/payment metrics surrounding an oncology biologic. ADVI did this by identifying key operational issues related to implementing IBP and quantitatively modeling the impact of discounting to product ASP.

Interested in hearing more from us?

Receive customized email alerts from the ADVI team